Stroke biomarkers aims to be an online resource of information about biomarkers associated with different features of the cerebrovascular disease. This website is administered by the Neurovascular Research Laboratory, located in Barcelona (Spain).
By the moment, we will publish information about proteins that have been associated with any of the aforementioned indications. We consider evidence of a potential role as biomarker for a specific indication when at least three publications had described that association; or when a number greater than 200 individuals have been included. Only articles written in English and Spanish will be included.
Stroke biomarkers attempts to be a live website that will be continuously updated. In the next future, we will include also information about other molecules, such as lipids or miRNAs.
The Neurovascular Research Laboratory
Our group identified for the first time the deleterious role of new molecules not described previously in human stroke such as several matrix metalloproteinases (MMP-9, MMP-13) or TAFI [1, 2]. Later on we noticed that this may have therapeutic implications since measuring those in the bloodstream might predict the occurrence of bleeding complications (MMP-9, VAP-1) [3, 4] and resistance to recanalization (inhibitors of fibrinolysis such as PAI -1 and TAFI)  among stroke patients receiving thrombolytic therapy, which might ensure the safety and efficacy of the treatment.
Since then we began to actively look for such a kind of biomarkers using different approaches and we succeed identifying new ones for some useful clinical indications such as prognostic and diagnostic during the acute phase of stroke: UFD1, endostatin or osteopontin [6, 7, 8]. Some of this research has been conducted with international stroke-biomarkers researchers. Thanks to those networks, we have participated in the description of the proteomes of brain tissue and microdialysates after human ischemic stroke [9, 10] and of the transcriptome of human intracranial hemorrhage , which has allowed the identification of new promising candidate biomarkers.
In one of these exploratory studies, we screened an antibodies library, with more than 150 candidates, and we identified a panel of biomarkers associated with the diagnosis and the prognosis of stroke, with near 100% sensitivity (unpublished results). This panel of biomarkers will be tested in a larger cohort (about 1,600 individuals), which is being enrolled in a Spanish multicentre study: the STR01 (StrokeChip).
Moreover, we are involved in the international EuroHYP-1 trial, in which information from tens of biomarkers will be obtained in thousands of, mainly, European patients.
1. Rosell A et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke. 2005, 36(7):1415-20.
2. Montaner J et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003, 34(4):1038-40.
3. Montaner J et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003, 107(4):598-603.
4. Hernandez-Guillamon M et al. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke. 2010, 41(7):1528-35.
5. Fernandez-Cadenas I et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost. 2007, 5(9):1862-8.
6. Allard L et al. Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke. Biomark Insights. 2007, 2:155-64.
7. Navarro-Sobrino M et al. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis. 2011, 216(1):205-11.
8. Mendioroz M et al. Osteopontin predicts long-term functional outcome among ischemic stroke patients. J Neurol. 2011, 258(3):486-93.
9. Cuadrado E et al. The proteome of human brain after ischemic stroke. J Neuropathol Exp Neurol. 2010, 69(11):1105-15.
10. Dayon L et al. Brain extracellular fluid protein changes in acute stroke patients. J Proteome Res. 2011, 10(3):1043-51.
11. Rosell A et al. Brain perihematoma genomic profile following spontaneous human intracerebral hemorrhage. PLoS One. 2011, 6(2):e16750.